These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The work of the Leeds Malignant Hyperpyrexia Unit, 1971-84. Ellis FR; Halsall PJ; Harriman DG Anaesthesia; 1986 Aug; 41(8):809-15. PubMed ID: 3752463 [TBL] [Abstract][Full Text] [Related]
3. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446 [TBL] [Abstract][Full Text] [Related]
4. Malignant hyperpyrexia occurring in a second Johannesburg family. Isaacs H; Barlow MB Br J Anaesth; 1973 Aug; 45(8):901-6. PubMed ID: 4753688 [No Abstract] [Full Text] [Related]
5. Malignant hyperpyrexia induced by nitrous oxide and treated with dexamethasone. Ellis FR; Clarke IM; Appleyard TN; Dinsdale RC Br Med J; 1974 Nov; 4(5939):270-1. PubMed ID: 4425856 [No Abstract] [Full Text] [Related]
6. Histological, histochemical and ultramicroscopic findings in muscle biopsies from carriers of the trait for malignant hyperpyrexia. Isaacs H; Frere G; Mitchell J Br J Anaesth; 1973 Aug; 45(8):860-8. PubMed ID: 4753682 [No Abstract] [Full Text] [Related]
10. Identification of susceptibility to malignant hyperpyrexia. Moulds RF; Denborough MA Br Med J; 1974 May; 2(5913):245-7. PubMed ID: 4827071 [TBL] [Abstract][Full Text] [Related]
11. Central core disease associated with elevated creatine phosphokinase levels. Two members of a family known to be susceptible to malignant hyperpyrexia. Isaacs H; Barlow MB S Afr Med J; 1974 Mar; 48(15):640-2. PubMed ID: 4823722 [No Abstract] [Full Text] [Related]
12. Clinical, electrophysiological and pathological studies on malignant hyperpyrexia. Bradley WG; Ward M; Murchison D; Hall L; Woolf N Proc R Soc Med; 1973 Jan; 66(1 Pt 1):67-8. PubMed ID: 4690062 [No Abstract] [Full Text] [Related]